Intimation of Q2 & H1 FY27- Earnings Presentation

October 19, 2026 DCS-CRD Listing Compliance BSE Limited National Stock Exchange of India Limited First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Phiroze Jeejeebhoy Towers Plot No. C/1, ‘G’ Block, Bandra- Kurla Complex Dalal Street, Fort Mumbai 400001 Bandra East Mumbai 400051 Fax No.2272 3121/2037/2039 Fax No.2659 8237/8238 Stock Code: 543213 Stock Code: ROSSARI Dear Sir/Madam, Subject.: Q2 & H1 FY27 Earnings Presentation Please find enclosed a copy of the Earnings Presentation for the quarter and half year ended September 30, 2026. The same may please be taken on record and suitably disseminated to all concerned. Thanking you, Yours Sincerely, For Rossari Biotech Limited Parul Gupta Company Secretary & Head - Legal Membership No.: A38895 Encl.: as above ROSSARI BIOTECH LIMITED Q2FY27 Investor Presentation Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Rossari Biotech Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company. Key Highlights Financial Highlights Company Overview Growth Levers Historical Financials 2 Q2FY27 Performance Highlights Management Commentary Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said We delivered robust consolidated growth of 19% YoY in Q2FY27, achieving a record quarterly revenue of Rs. 698 crores. The performance was driven by healthy momentum in the domestic business and the continued expansion of our international presence. We concluded the first half of FY27 on a strong note, with consolidated revenue of Rs. 1,395 crores in H1FY27, a healthy growth of 23% YoY. The growth was broad-based, led by healthy volume, improved product mix and focused execution across our businesses. During Q2FY27, the HPPC, TSC and AHN businesses delivered YoY growth of 18%, 26% and 11%, respectively. Performance was supported by a higher contribution from value-added products and improved wallet share with customers across end-user industries. We continue to operate under dynamic business environment marked by raw material volatility, geopolitical uncertainty and cautious customer behaviour. Despite of these headwinds in Q2FY27 we maintained the gross margin at ~32% level and EBITDA margin at ~12.5% level. During H1FY27, we made progress in strengthening our balance sheet and improving cash flow generation. Our net working capital cycle improved to 86 days as of 30 September 2026, compared with 97 days as of 31 March 2026. Further, net debt declined to Rs. 221 crores from Rs. 281 crores over the same period. We are pleased to announce that the Board has approved the leasing of land to Rossari International Limited Company (RILC), our wholly owned subsidiary, for setting up a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA). This builds on the in-principle approval granted by the Board earlier and marks a key milestone in Rossari’s international growth journey. Our strategic initiatives are progressing in the right direction. These include monetising non-core assets, rationalising lower-margin businesses and improving the product mix. We remain confident that operating leverage, scale benefits and these initiatives will support progressive improvement in profitability. With strong R&D capabilities, expanding capacities, a healthy balance sheet and a growing global footprint, we are well placed to build an integrated, intelligent and impactful specialty chemicals platform and deliver sustained long-term growth. Key Highlights Financial Highlights Company Overview Growth Levers Historical Financials 4 Q2FY27 – Key Business Updates Kingdom of Saudi Arabia (KSA) Facility Home, Personal Care and Performance Chemicals • The Board has approved the leasing of land by Rossari International • Successfully completed the Stage 1 EXCiPACT audit for Pharma business Limited Company, a wholly owned subsidiary, for setting up a greenfield • Strategically expanding our preservative and mild surfactant portfolio manufacturing facility in the Kingdom of Saudi Arabia (KSA) • Agro business in general was sluggish because of El Niño • Commissioned one of India’s largest EO storage facility at our Unitop site Financial Highlights – Q2FY27 • Highest-ever quarterly revenue of Rs. 697.6 crores, a 19.0% growth on y- Textile Specialty Chemicals o-y basis • New geographies added - Peru and Indonesia • Highest-ever quarterly EBITDA of Rs. 87.0 crores, a 20.9% growth on y-o-y basis • New products introduced - • Profit After Tax stood at Rs. 38.9 crores, remained subdued due to higher o Yarn and thread lubricants portfolio expanded depreciation arising from investments in long-term projects o Spin-finish for Fully Drawn Yarn (FDY) • Highest-ever export sales of Rs. 216.4 crores, a 33.8% growth on y-o-y o New product category for denim processing basis • Strong Cash flow from Operations at Rs. 131 crores Animal Health and Nutrition • Net working capital improved to 86 days as of September 2026 from 97 days as of March 2026. • New range of disinfectants introduced • Net debt declined to Rs. 221 crores from Rs. 281 crores as of March 2026 • Emulsifiers for poultry feed as new product category • Liquid enzymes for exports • Biosurfactant based gut health modulator for poultry Key Highlights Financial Highlights Company Overview Growth Levers Historical Financials 5 Key Financial Highlights Total Revenue Gross Profit (INR in crores) +23% 1,394.8 31.6% 31.6% 31.7% 30.6% Margin 1,129.8 +19% +19% 426.7 697.6 586.1 +19% 357.6 220.3 185.2 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 EBITDA Profit After Tax 12.3% 12.5% 12.4% 12.0% 6.3% 5.6% 6.2% 5.3% Margin +20% +5% 167.6 74.0 70.5 +21% 139.8 +6% 87.0 36.9 38.9 71.9 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Key Highlights Financial Highlights Company Overview Growth Levers Historical Financials 6 Q [Showing first 8,000 characters — download PDF for full document]